The estimated Net Worth of Bradley Ottinger is at least $338 Mille dollars as of 16 March 2023. Bradley Ottinger owns over 8,463 units of Axogen stock worth over $338,149 and over the last 4 years Bradley sold AXGN stock worth over $0.
Bradley has made over 2 trades of the Axogen stock since 2022, according to the Form 4 filled with the SEC. Most recently Bradley exercised 8,463 units of AXGN stock worth $112,389 on 16 March 2023.
The largest trade Bradley's ever made was exercising 15,500 units of Axogen stock on 1 June 2022 worth over $205,840. On average, Bradley trades about 4,793 units every 58 days since 2020. As of 16 March 2023 Bradley still owns at least 25,463 units of Axogen stock.
You can see the complete history of Bradley Ottinger stock trades at the bottom of the page.
Bradley's mailing address filed with the SEC is 13631 PROGRESS BOULEVARD, SUITE 400, , ALACHUA, FL, 32615.
Over the last 13 years, insiders at Axogen have traded over $73,805,978 worth of Axogen stock and bought 504,297 units worth $3,119,117 . The most active insiders traders include James E Deerfield Mgmt L.P...., Guido J Neels e Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of $455,132. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth $158,085.
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
Axogen executives and other stock owners filed with the SEC include: